Expanding its vascular access products
3M has agreed to buy Ivera Medical, a US manufacturer of healthcare products that disinfect and protect devices used for access into a patient’s bloodstream.
Financial terms of the transaction, which is expected to close in the first half of this year, have not been disclosed.
Ivera, based in San Diego, California, employs approximately 60 people and has annual sales of around US$30m.
3M said the addition of Ivera will enhance its vascular access product offerings at a time when healthcare facilities are seeking cost-effective solutions that improve patient health outcomes, particularly in the area of hospital acquired infections (HAIs), including catheter-related blood stream infections. The company said reducing the risk of such infections is a major focus of healthcare facilities around the world.
Ivera makes IV port connector caps, sold under the Curos brand, which are used to disinfect and act as a barrier to contamination on devices that provide access to IV lines. These products complement 3M’s Tegaderm CHG (Chlorhexidine Gluconate) brand of dressings to secure IV drips.
Bill Cruise, Vice President and General Manager, 3M Critical & Chronic Care Solutions Division, said 3M's products play an important role in helping to reduce complications for patients with IV catheters.
'Together with Ivera, we can bring a broader array of vascular access solutions to more healthcare systems worldwide,' he said.
In addition to the Tegaderm dressings, 3M’s products that help prevent and treat critical and chronic conditions include medical tapes, skincare products, bandages and wraps, and skin closures.